首页> 外文期刊>Oral oncology >Clinical characteristics and patterns of failure in the parotid region after intensity-modulated radiotherapy for nasopharyngeal carcinoma
【24h】

Clinical characteristics and patterns of failure in the parotid region after intensity-modulated radiotherapy for nasopharyngeal carcinoma

机译:鼻咽癌调强放疗后腮腺区功能衰竭的临床特征

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: To discuss the clinical characteristics and patterns of failure in the parotid region after intensity-modulated radiotherapy for nasopharygeal carcinoma.Materials and Methods: We retrospectively reviewed the charts of 716 patients with nasopharygeal carcinoma who underwent intensity-modulated radiotherapy in our centre from January 2005 to December 2010. Disease recurred in a spared parotid gland in 10 patients (1.4%). There were 2 females and 8 males with a median age of 38.5 (34-53) years. The most common presenting symptom was a swelling in pre-auricular region (7/10). Parotid glands were spared bilaterally in these patients. None of these patients had undergone previous radiotherapy or surgical treatment of the head and neck. The location of periparotid failures were transferred to the pretreatment planning computed tomography for dosimetry analysis.Results: The median time from day 1 of radiotherapy to periparoid recurrence was 17.4 (4.4-40.5) months. The median survivial after periparoid recurrence was 25.1 (5.0-74.5) months. There were 9 (90%) patients with lateral retropharyngeal lymphadenopathy. Seven of the periparotid failures were marginal. Of the 7 marginal failures, 6 occurred at the ipslateral parotid of the primary tumor centre. The average mean dose of the ipslateral parotid was 38.1 (32.3-44.1) Gy. Conclusion: Periparotid recurrence is an uncommon pattern of failure after definitive intensity-modulated radiotherapy for nasopharygeal carcinoma. To reduce the risk of periparotid recurrence,one possible strategy is to lessen the dose constraint criteria to ipslateral parotid of the primary tumor centre especially for nasopharygeal carcinoma with lateral retropharyngeal lymphadenopathy.
机译:目的:探讨鼻咽癌调强放疗后腮腺区的临床特点和失败模式。材料与方法:回顾性分析1月份以来我中心接受强度调治放疗的716例鼻咽癌患者的病历。 2005年至2010年12月。该疾病在剩余的腮腺中再发10例患者(占1.4%)。有2位女性和8位男性,平均年龄为38.5(34-53)岁。最常见的症状是耳前区肿胀(7/10)。这些患者的双侧腮腺均未幸免。这些患者均未接受过头颈部放疗或手术治疗。结果:从放疗第1天到骨par复发的中位时间为17.4(4.4-40.5)个月。复发性中位生存期为25.1(5.0-74.5)个月。有9例(90%)的患者有咽后外侧淋巴结肿大。腮腺周围衰竭中有7例是边缘性的。在7例边缘性衰竭中,有6例发生在原发肿瘤中心的腮腺旁。患侧腮腺的平均平均剂量为38.1(32.3-44.1)Gy。结论:确定的强度调制放射治疗鼻咽癌后,periparotid复发是一种罕见的失败模式。为了降低腮腺周围复发的风险,一种可能的策略是降低原发肿瘤中心的后腮腺的剂量限制标准,特别是对于鼻咽后侧淋巴结肿大的鼻咽癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号